Web11 apr. 2024 · BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of … Web30 mrt. 2024 · To make matters worse, some of the academic credentials claimed by Dr. Litton in Athira’s SEC filings and website were false. Specifically, until just days ago, Dr. Litton claimed to have...
Mark Litton - President & Chief Executive Officer @ Athira …
Web10 apr. 2024 · Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. About the company Risk Analysis Earnings are forecast to decline by an average of 12.4% per year for the next 3 years Makes less than USD$1m in revenue ($0) Web21 okt. 2024 · Litton has demonstrated exemplary leadership of the Athira team since joining the Company in July 2024, and especially since assuming day-to-day leadership … lax hertz address
Athira shareholder targets CEO Mark Litton in scathing letter
Web23 mrt. 2024 · Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to … Web13 apr. 2024 · Mark Litton, CEO of Athira Pharma, a Washington-based biotech working to develop drugs for Alzheimer’s and other neurodegenerative diseases, told Healthcare Brew the company has been conservative with its cash and is hoping to have data next year. Web8 feb. 2024 · Athira went public in 2024. “Our strong balance sheet, with cash of $339.4-million as of Sept. 30, 2024, will support our clinical programs through upcoming key inflection points,” Dr. Litton contends. Athira is currently evaluating ATH-1017 in the ACT-AD Phase 2 study in mild-to-moderate AD dementia. lax hermes